Adjuvant and neoadjuvant therapies in high risk localized prostate cancer

被引：0
|
作者：
Giannakopoulos, X.
Stagikas, D.
Charalabopoulos, A.
Sofikitis, N.
Charalabopoulos, K.
机构：
[1] Univ Ioannina, Dept Physiol, Clin Unit, Fac Med, GR-45221 Ioannina, Greece
[2] Univ Ioannina, Dept Urol, GR-45221 Ioannina, Greece
[3] Peterborough Hosp, Dept Surg, Peterborough, Cambs, England
来源：
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2006年 / 25卷 / 04期
关键词：
prostate cancer; adjuvant therapy; neoadjuvant therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In this review article adjuvant and neoadjuvant therapies in patients at high risk for localized prostate cancer are presented in some detail. Adjuvant hormone therapy by antiandrogens as well as antineoplastic chemotherapeutic agents such as estramustine and taxanes are referred. Neoadjuvant therapies in addition to systemic therapy before or after local treatment for prostate cancer may improve the outcome of high risk patients otherwise destined to treatment fail. Data regarding some substances used in neoadjuvant therapies such as androgen deprivation therapy and use of rapamycin with its analogs, as well as some novel therapeutic approach strategies are also discussed.
引用
收藏
页码：469 / 473
页数：5
相关论文
共 50 条
  • [1] Neoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer
    Nakabayashi M.
    Oh W.K.
    [J]. Current Treatment Options in Oncology, 2004, 5 (5) : 349 - 355
  • [2] Neoadjuvant therapies for surgical management of high-risk, localized prostate cancer
    Mikkilineni, Nina
    Hyams, Elias S.
    [J]. TRANSLATIONAL CANCER RESEARCH, 2018, 7 : S662 - S675
  • [3] Neoadjuvant and Adjuvant Therapies in Prostate Cancer
    Schutz, Fabio A. B.
    Oh, William K.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2010, 37 (01) : 97 - +
  • [4] Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer
    Dorff, Tanya B.
    Glode, L. Michael
    [J]. CURRENT OPINION IN UROLOGY, 2013, 23 (04) : 366 - 371
  • [5] Neoadjuvant and adjuvant treatment in high-risk prostate cancer
    Bandini, Marco
    Fossati, Nicola
    Gandaglia, Giorgio
    Preisser, Felix
    Dell'Oglio, Paolo
    Zaffuto, Emanuele
    Stabile, Armando
    Gallina, Andrea
    Suardi, Nazareno
    Shariat, Shahrokh F.
    Montorsi, Francesco
    Karakiewicz, Pierre I.
    Briganti, Alberto
    [J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (04) : 425 - 438
  • [6] Neoadjuvant therapy for high-risk localized prostate cancer
    Evan Y. Yu
    William K. Oh
    [J]. Current Oncology Reports, 2003, 5 (3) : 250 - 257
  • [7] Adjuvant and salvage radiotherapy after neoadjuvant therapy and radical prostatectomy for high-risk localized prostate cancer
    Ravi, Praful
    Kwak, Lucia
    Devlies, Wout
    Xie, Wanling
    Chipidza, Fallon
    Yang, Xiaoyu
    Bubley, Glenn
    Kaplan, Irving
    Kibel, Adam S.
    Nguyen, Paul
    Taplin, Mary-Ellen
    [J]. PROSTATE, 2024, 84 (04): : 342 - 348
  • [8] Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer
    Garzotto, M
    Myrthue, A
    Higano, CS
    Beer, TM
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (03) : 254 - 259
  • [9] Combination therapies in progressive high risk forms of prostate cancer (localized or not)
    Monnier, Laurie
    Culine, Stephane
    Cormier, Luc
    [J]. PRESSE MEDICALE, 2017, 46 (10): : 940 - 946
  • [10] Current and emerging therapies for localized high-risk prostate cancer
    Moris, Lisa
    Devos, Gaetan
    Van den Broeck, Thomas
    Milonas, Daimantas
    Albersen, Maarten
    Berghen, Charlien
    De Meerleer, Gert
    Devlies, Wout
    Everaerts, Wouter
    Gevaert, Thomas
    Van Poppel, Hendrik
    Claessens, Frank
    Joniau, Steven
    [J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (03) : 267 - 282
12345